Addition of New Monotherapy Cohort for Additional Cancer Types
and Combination Therapy Parts

ABL Bio, a company specializing in bispecific antibodies, announced on June 4 that it has submitted an amended Investigational New Drug (IND) application for its bispecific antibody immuno-oncology therapy ABL503 (Ragistomig) to the Ministry of Food and Drug Safety in Korea.


ABL503 is a bispecific antibody candidate targeting PD-L1 and 4-1BB, which is currently being co-developed by ABL Bio and the U.S. biotechnology company NovaBridge Biosciences. ABL503 was designed to overcome the limitations of existing PD-(L)1 inhibitors, such as resistance and low response rates. At present, a monotherapy phase 1 clinical trial comprising Dose Escalation, Dose Expansion, and Tumor Expansion parts is underway in both the United States and Korea for patients with solid tumors.

ABL Bio Submits IND Amendment for Phase 1 Trial to Evaluate ABL503 Combination Therapy View original image

Through this IND amendment, ABL Bio has added a new monotherapy cohort targeting additional cancer types to the Tumor Expansion part of the phase 1 trial. The company also plans to newly conduct Dose Escalation and Dose Expansion parts to evaluate the combination therapy of ABL503 with a PD-1 inhibitor. This phase 1 clinical trial will be conducted at more than eight sites in Korea and the United States.


The primary endpoints of the ABL503 phase 1 trial are safety and tolerability, based on Dose-Limiting Toxicity (DLT), Adverse Events (AE), Cytokine Release Syndrome (CRS), and Infusion-Related Reactions (IRR). In addition, ABL Bio will also evaluate preliminary anti-tumor activity indicators, such as Objective Response Rate (ORR), Duration of Response (DOR), and Disease Control Rate (DCR).


Lee Sanghoon, CEO of ABL Bio, stated, "With this IND amendment, we have expanded the clinical development strategy for ABL503 from monotherapy to combination therapy." He added, "Another candidate, ABL111 (Givastomig), which is based on the 4-1BB bispecific antibody platform Grabody-T, has attracted much attention thanks to encouraging clinical data from combination therapy with chemotherapy and PD-1 inhibitors. We expect to see positive results from the combination therapy part of the ABL503 trial as well."



ABL Bio is developing a diverse pipeline at both preclinical and clinical stages, based on its bispecific antibody platform Grabody. Clinical projects for 10 pipeline candidates—including ABL301 (SAR446159), ABL001 (Tovecimig), ABL111 (Givastomig), ABL503 (Ragistomig), ABL105 (Nesfrotamig), ABL104 (YH32364), ABL103, ABL202 (CS5001/LCB71), ABL206 (NEOK001), and ABL209 (NEOK002)—are underway in various countries, including the United States, China, Australia, and Korea. The follow-up clinical trial for ABL301 (SAR446159), for which phase 1 in the U.S. has been completed, will be conducted by Sanofi. ABL001 (Tovecimig), which is in phase 2/3 clinical trials for patients with cholangiocarcinoma, has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). ABL111 (Givastomig), co-developed with NovaBridge, has initiated a phase 2 clinical trial for combination therapy with Nivolumab and chemotherapy, and additional data from the phase 1b will be presented at a global conference in the second half of this year. In addition, ABL Bio continues to research and develop several preclinical pipeline candidates, including bispecific antibody ADCs and dual payload ADCs.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing